[Novel drugs provide better therapy for prostate cancer]

Area of Science:

• Oncology
• Pharmacology
• Urology

Background:

• Prostate cancer therapy has advanced with the availability of several effective drugs.
• These treatments are utilized following the development of castration resistance and are also being investigated for earlier-stage prostate cancer.
• Novel hormonal therapies and cytotoxic agents represent significant progress in managing advanced prostate cancer.

Purpose of the Study:

• To review the current landscape of novel drugs available for prostate cancer therapy.
• To highlight the application of these drugs in both castration-resistant and earlier stages of prostate cancer.
• To underscore the ongoing research into optimal drug sequencing and combination strategies.

Main Methods:

• Review of recently developed and approved prostate cancer therapeutics.
• Categorization of drugs into novel hormonal agents and cytotoxic agents.
• Identification of drugs used for managing bone metastases and their complications.

Main Results:

• Novel hormonal agents such as degarelix, enzalutamide, and abiraterone are available.
• Effective cytotoxic agents include cabazitaxel, denosumab for bone metastasis complications, and radium-233 chloride for bone metastases.
• These drugs are employed post-castration resistance and are being studied in earlier disease stages.

Conclusions:

• A range of novel drugs has expanded therapeutic options for prostate cancer.
• Optimal sequencing and combination of these agents are critical areas of ongoing intensive research.
• Further studies are needed to define the most effective treatment paradigms for prostate cancer patients.